ANDA 65517, held by Aurobindo Pharma. Cefotaxime Sodium.
As of Nov 16, 2026, ANDA 65517 (Cefotaxime Sodium), held by Aurobindo Pharma, was first approved by FDA on Nov 5, 2009, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2009 | Original application | Approved | None posted |
| Cefotaxime SodiumEQ 500MG BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Cefotaxime SodiumEQ 1GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Cefotaxime SodiumEQ 2GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters